Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last --
Change Today 0.00 / 0.00%
Volume 0.0
4503 On Other Exchanges
Symbol
Exchange
4503 is not on other exchanges.
All times are local (Market data is delayed by at least 15 minutes).

astellas pharma inc (4503) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
0.0
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ASTELLAS PHARMA INC (4503)

Related News

No related news articles were found.

astellas pharma inc (4503) Related Businessweek News

View More BusinessWeek News

astellas pharma inc (4503) Details

Astellas Pharma Inc. manufactures, markets, and imports/exports pharmaceutical products worldwide. The company focuses on the therapeutic areas of urology, immunology and infectious diseases, oncology, neuroscience, and diabetes mellitus complications and kidney diseases. The company offers immunosuppressants, including Prograf, and Advagraf/ Graceptor/ ASTAGRAF XL; Vesicare and Betanis/Myrbetriq/BETMIGA for overactive bladder treatment; and Harnal/Omnic for functional symptoms associated with benign prostatic hyperplasia. It also provides Funguard/MYCAMINE, a candin antifungal agent; Protopic for atopic dermatitis; Eligard, XTANDI, and Gonax for prostate cancer treatment; Micardis, including Micombi and Micamlo BP for hypertension; Celecox, an anti-inflammatory agent; Symbicort for adult bronchial asthma and chronic obstructive pulmonary disease; Geninax for oral quinolone antibiotic; Bonoteo for osteoporosis; Cimzia for the treatment of adult patients with rheumatoid arthritis; and Suglat for type two diabetes treatments. In addition, the company offers Lipitor products for the treatment of hypercholesterolemia; Gaster for peptic ulcers and gastritis; Myslee for insomnia; Seroquel for schizophrenia; Regnite for restless legs syndrome; Kiklin for hyperphatemia treatments, as well as Lexiscan and Adenoscan, which are pharmacologic stress agents; and Tarceva for the treatment of lung and pancreatic cancers. Further, it provides Acofide for functional dyspepsia; Bisono Tape, a transdermal hypertension medication; diarrhea-predominant OD tablets; and dificlir for clostridium difficile infections. It has a strategic alliance with Amgen Inc. and ClearPath Development Company; and collaborative agreements with Immuno-Biological Laboratories Co., Ltd., Cytokinetics, Inc., Mitokyne, Inc., QIAGEN N.V., and Dana-Farber Cancer Institute. The company was founded in 1923 and is headquartered in Tokyo, Japan.

17,649 Employees
Last Reported Date: 06/18/14
Founded in 1923

astellas pharma inc (4503) Top Compensated Officers

Chief Executive Officer, President and Repres...
Total Annual Compensation: ¥170.0M
Compensation as of Fiscal Year 2014.

astellas pharma inc (4503) Key Developments

Vical Incorporated Enters License Agreement with Astellas Pharma Inc. to Develop and Commercialize ASP2397

On March 24, 2015, Vical Incorporated (Vical) entered into a license agreement with Astellas Pharma Inc. (Astellas) granting Vical an exclusive, worldwide license to develop and commercialize ASP2397, an antifungal compound being developed for the treatment of invasive Aspergillus infections. Under the terms of the License Agreement, Vical paid Astellas an initial license fee of $250,000 in cash and 861,216 shares of Vical's common stock. The License Agreement provides for potential development, regulatory and sales milestone payments totaling up to $99.5 million, as well as tiered single-digit royalty payments based on net sales of licensed products. The royalty payments are subject to reduction on a country-by-country basis in certain circumstances where there is not exclusivity in the country. Vical is responsible for the worldwide development, manufacturing and commercialization of licensed products, at its cost, and is required to use commercially reasonable efforts with respect to such development and commercialization activities. Astellas agreed to complete certain IND-enabling non-clinical studies and to conduct a technology transfer with respect to ASP2397 manufacturing technology at Vical's request within a specified period of time. Astellas holds the first right to prosecute and to enforce all licensed patents under the License Agreement throughout the world, and Vical has certain step-in enforcement rights. During the term of the License Agreement, both parties are prohibited from manufacturing or commercializing any competing antifungal product that acts through the same mechanism of action as ASP2397.

Astellas Pharma Europe Announces New Enzalutamide Data Presented During Plenary Presentations at the 2015 European Association of Urology Congress

Astellas Pharma Europe Ltd. announced new data from the Phase 2 TERRAIN trial of enzalutamide compared to bicalutamide in metastatic castration-resistant prostate cancer (CRPC), as well as an updated overall survival analysis from the placebo-controlled Phase 3 PREVAIL trial of enzalutamide in chemotherapy-naive metastatic CRPC. The data were presented during a plenary session at the 2015 European Association of Urology (EAU) Congress in Madrid, Spain. The Phase 2 TERRAIN trial enrolled 375 patients in North America and Europe. The trial enrolled patients with metastatic prostate cancer whose disease progressed despite treatment with a luteinising hormone-releasing hormone (LHRH) analogue therapy or following surgical castration. The primary endpoint of the trial was progression-free survival (PFS), defined as time from randomisation to centrally confirmed radiographic progression, skeletal related event, initiation of new anti-neoplastic therapy or death, whichever occurred first. The trial was designed to evaluate enzalutamide at a dose of 160 mg taken orally once daily versus bicalutamide at a dose of 50 mg taken once daily, the approved dose in combination with a LHRH analogue.

Astellas and Medivation Announce New Enzalutamide Data Presented During Plenary Presentations at the 2015 European Association of Urology Congress

Astellas Pharma Inc. and Medivation, Inc. announced new data from the Phase 2 TERRAIN trial of enzalutamide compared to bicalutamide in metastatic castration-resistant prostate cancer (CRPC), as well as an updated overall survival analysis from the placebo-controlled Phase 3 PREVAIL trial of enzalutamide in chemotherapy-naive metastatic CRPC. The data were presented during a plenary session at the 2015 European Association of Urology (EAU) Congress in Madrid, Spain. The Phase 2 TERRAIN trial enrolled 375 patients in North America and Europe. The trial enrolled patients with metastatic prostate cancer whose disease progressed despite treatment with a luteinizing hormone-releasing hormone (LHRH) analogue therapy or following surgical castration. The primary endpoint of the trial was progression-free survival (PFS), defined as time from randomization to centrally confirmed radiographic progression, skeletal-related event, initiation of new anti-neoplastic therapy or death, whichever occurred first. The trial was designed to evaluate enzalutamide at a dose of 160 mg taken orally once daily versus bicalutamide at a dose of 50 mg taken once daily, the approved dose in combination with an LHRH analogue.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4503:JP ¥1,950.00 JPY -27.50

4503 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Baxter International Inc $68.55 USD +0.53
Becton Dickinson and Co $144.59 USD +1.38
Boston Scientific Corp $17.83 USD +0.39
CSL Ltd A$91.85 AUD +0.15
Mylan NV $61.63 USD -0.25
View Industry Companies
 

Industry Analysis

4503

Industry Average

Valuation 4503 Industry Range
Price/Earnings 35.0x
Price/Sales 3.6x
Price/Book 3.1x
Price/Cash Flow 23.5x
TEV/Sales 3.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ASTELLAS PHARMA INC, please visit www.astellas.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.